<DOC>
	<DOCNO>NCT02165215</DOCNO>
	<brief_summary>This Phase III , randomize , double blind , parallel group , placebo-controlled , multicenter study investigate efficacy safety etrolizumab maintenance remission participant moderately severely active ulcerative colitis ( UC ) na√Øve TNF inhibitor refractory intolerant prior immunosuppressant and/or corticosteroid treatment .</brief_summary>
	<brief_title>A Study Efficacy Safety Etrolizumab Treatment Maintenance Disease Remission Ulcerative Colitis Participants Who Are Naive Tumor Necrosis Factor ( TNF ) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Moderately severely active UC determine MCS assessment Evidence UC extend minimum 20 centimeter ( cm ) anal verge determine baseline endoscopy ( flexible sigmoidoscopy colonoscopy ) perform 4 10 day prior Day 1 Naive treatment antiTNF therapy Participants must inadequate response , loss response , intolerance prior corticosteroid and/or immunosuppressant treatment Background regimen UC may include oral 5aminosalicylate ( 5ASA ) , oral corticosteroid , budesonide multimatrix system ( MMX ) , probiotic , azathioprine ( AZA ) , 6mercaptopurine ( 6MP ) , methotrexate ( MTX ) dose stable screen period Use highly effective contraception Must receive colonoscopy within past year willing undergo colonoscopy lieu flexible sigmoidoscopy screen A history current condition disease affect digestive tract , indeterminate colitis , Crohn 's disease , fistulas abdominal abscess , colonic mucosal dysplasia , intestinal obstruction , toxic megacolon , unremoved adenomatous colonic polyp Prior plan surgery UC Past present ileostomy colostomy Have receive nonpermitted inflammatory bowel disease ( IBD ) therapy ( include natalizumab , vedolizumab , efalizumab ) state protocol Chronic hepatitis B C infection , human immunodeficiency virus ( HIV ) tuberculosis ( active latent )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>